Olema Pharmaceuticals, Inc.

OLMA

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Rock Springs Capital RA Capital Management Perceptive Advisors

Position Trend

Feb 13, 2026

$14.2M

1 fund

Feb 17, 2026

$204.0M

4 funds

+1334% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Nov 14, 2022

SC 13G/ARA Capital Management0.0%May 16, 2022

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 98,240Value: $2.5M

**Signal Note: Rock Springs Capital initiates position in OLMA** Specialist healthcare investor Rock Springs Capital's $2.5M entry into Olema suggests conviction in the company's clinical pipeline, likely driven by upcoming data catalysts for OL-M01 (ER/PR+ breast cancer) or pipeline advancement. The 98k share position represents a meaningful but measured bet, consistent with a concentrated long/short strategy focused on clinical-stage validation rather than market cap. Watch for upcoming trial readouts or regulatory milestones that would trigger the thesis.

RA Capital ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MIRM4 funds SION4 funds IVVD4 funds KYMR4 funds IRON4 funds RVMD4 funds AMLX3 funds DXCM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# OLMA Signal Note RA Capital's $65M entry into Olema signals confidence in OLM101, a selective CDK4/6 inhibitor for hormone receptor-positive breast cancer positioned as an alternative to Palbociclib/Ribociclib with potentially improved tolerability. The timing suggests conviction ahead of Phase 3 data readout (expected late 2024/early 2025), which will be critical for differentiation in a crowded CDK4/6 market where label expansion and patient switching remain the primary value drivers.